Related Experiment Video

Updated: May 21, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K

YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas

Miao Wang1, Siyu Qian1, Yue Zhang1

  • 1Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.

Current Cancer Drug Targets
|March 19, 2025
PubMed
Abstract

Insights

Yippee Like 1 (YPEL1) protein shows dual roles in cancer. Silencing YPEL1 in NK/T cell lymphoma models induced cell death and reduced tumor growth, suggesting YPEL1 as a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • Yippee Like 1 (YPEL1) is a nuclear protein regulating cell cycle, senescence, and development.
  • YPEL1 has a dual role in cancer, acting as either an antitumor or tumor-promoting factor.

Purpose of the Study:

  • Investigate the role of YPEL1 in various cancers.
  • Determine YPEL1's potential as a therapeutic target for NK/T cell lymphoma.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) for expression analysis.
  • Examined YPEL1 protein levels in YT and gemcitabine-resistant YT (YT/Gem-R) cell lines.
  • Performed YPEL1 knockdown experiments in vitro and in vivo xenograft models.

Main Results:

  • Aberrant YPEL1 expression was observed across multiple cancers.
  • High YPEL1 expression correlated with poorer patient survival, while low expression indicated better outcomes.
  • YPEL1 knockdown induced apoptosis and autophagy in YT and YT/Gem-R cells, and reduced tumor growth in xenografts.

Conclusions:

  • YPEL1 plays a significant role in NK/T cell lymphoma progression.
  • Targeting YPEL1 demonstrates therapeutic potential for NK/T cell lymphoma treatment.
Keywords:
YPEL1; YTYT/Gem-Rapoptosis.cancertumor

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

179

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454